{"metadata": {"source": "pubchem", "title": "Methadone | C21H27NO | CID 4095 - PubChem", "description": "Methadone | C21H27NO | CID 4095 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/4095", "drug": "Methadone", "cid": 4095, "char_count": 207830, "word_count": 28065, "doc_id": "doc_48", "num_chunks": 289, "chunk_id": "48::chunk_170", "document_index": 48, "latency_s": 1.5371042000042507, "prompt_toks": 53766, "completion_toks": 79, "relevance_score": 0.00036259004}, "content": "Drug: Methadone | cid: 4095\nSource: pubchem | Source description: Methadone | C21H27NO | CID 4095 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Addiction, abuse, and misuse of the drug: The FDA warns that methadone injection injection poses risks of opioid addiction, abuse, and misuse, potentially leading to a fatal overdose. A thorough risk-benefit evaluation is essential before prescribing methadone injection, and ongoing patient monitoring is crucial to detect and address any potential misuse.\n\n\n                    Context: \n                    This excerpt details important safety warnings related to methadone, emphasizing risks of addiction, misuse, and overdose associated with its injection form. It highlights the need for careful risk assessment and patient monitoring, situating it within the broader document's discussion of methadone's pharmacology, toxicity, and regulatory concerns. These warnings are essential for understanding methadone’s potential hazards and prescribed use precautions.\n                "}
{"metadata": {"source": "pubchem", "title": "Oxymorphone | C17H19NO4 | CID 5284604 - PubChem", "description": "Oxymorphone | C17H19NO4 | CID 5284604 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284604", "drug": "Oxymorphone", "cid": 5284604, "char_count": 101143, "word_count": 12715, "doc_id": "doc_56", "num_chunks": 137, "chunk_id": "56::chunk_74", "document_index": 56, "latency_s": 2.0620415000012144, "prompt_toks": 27809, "completion_toks": 87, "relevance_score": 0.00017536995}, "content": "Drug: Oxymorphone | cid: 5284604\nSource: pubchem | Source description: Oxymorphone | C17H19NO4 | CID 5284604 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Nalmefene is an alternative pure opioid antagonist, which may be administered as a specific antidote to respiratory depression resulting from opioid overdose. Since the duration of action of oxymorphone injection may exceed that of the antagonist, the patient should be kept under continued surveillance and repeated doses of the antagonist should be administered according to the antagonist labeling as needed to maintain adequate respiration.\n\n\n                    Context: \n                    This excerpt discusses the use of opioid antagonists in overdose treatment, specifically noting that nalmefene can be administered as a specific antidote for respiratory depression caused by oxymorphone overdose. It emphasizes the importance of continued patient surveillance and repeated dosing due to oxymorphone's longer duration of action. This information is relevant to the pharmacology and toxicity sections of the full document, which detail overdose management and antagonist use.\n                "}
{"metadata": {"source": "pubchem", "title": "Methadone | C21H27NO | CID 4095 - PubChem", "description": "Methadone | C21H27NO | CID 4095 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/4095", "drug": "Methadone", "cid": 4095, "char_count": 207830, "word_count": 28065, "doc_id": "doc_48", "num_chunks": 289, "chunk_id": "48::chunk_6", "document_index": 48, "latency_s": 1.735201399991638, "prompt_toks": 53767, "completion_toks": 75, "relevance_score": 0.00010975091}, "content": "Drug: Methadone | cid: 4095\nSource: pubchem | Source description: Methadone | C21H27NO | CID 4095 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    substances that increase the risk of harm or overdose. Provision of OAT is often combined with education about harm reduction including use of clean needles and injection supplies in an effort to reduce the risks associated with injection drug use such as contraction of HIV and Hepatitis C and other complications including skin infections, abscesses, or endocarditis.\n\n\n                    Context: \n                    This excerpt appears within the section on drug and medication safety, specifically discussing harm reduction strategies associated with opioid substitution therapy (OAT) such as methadone. It highlights that provision of OAT should be accompanied by education on safe injection practices to mitigate risks like infections and overdose, emphasizing the importance of harm reduction in the overall context of opioid treatment safety and public health information.\n                "}
